H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PAN subgroup compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAQ subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCN subgroup · patients with Helicobacter pylori infection
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PCN subgroup compared with 7 days (very low certainty).
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Flare‐ups or relapse (continuous) · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
2 findings from 1 review
Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (binary): definitive chemoradiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
1 finding from 1 review
Adverse effects of endoscopy therapy Adverse effects · patients with high‐risk bleeding ulcers
Epinephrine probably leads to higher adverse effects of endoscopy therapy Adverse effects compared with epinephrine and any second endoscopic method (moderate certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy (no special data in trial of Zhang 2006) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy (very low certainty).
1 finding from 1 review